Pfizer is letting people screen its proprietary compounds, says Derek Lowe at In the Pipeline. "As I understand it, you need to come to them with a reasonably formatted HTS assay, and there's a fee in the high hundreds of thousands to run the screen," Lowe writes, and that set-up doesn't strike him as "much of a moneymaker." Instead, he says it's probably a way for Pfizer to make deals with smaller companies since the compounds are likely covered by Pfizer patents.
Premium Trial: